The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure.

The MMRF identifies barriers slowing drug development, and creates new collaborative models with world-class partners to overcome those obstacles. Models include multicenter tissue banks; a genomics initiative, which mapped the myeloma genome for the first time; a clinical network of 21 centers (the MMRC) that has opened more than 50 clinical trials; a longitudinal study (CoMMpass) that will follow 1,000 patients, tracking clinical and genomic data, from diagnosis over at least 5 years to inform precision medicine approaches; and an open-access gateway (MMRF Researcher Gateway) to make CoMMpass data widely available to researchers worldwide.

The organization also educates and empowers the myeloma patient community by providing supportive services and resources that include patient support nurses, educational symposia, online education, the MMRF CoMMunity Gateway, and a Web-based clinical trial matching tool.  A total of 90% of the funds raised by the MMRF support research and related programming.

For more information about the MMRF, please visit www.themmrf.org.

Information about this independent organization is provided as an additional resource for obtaining information related to multiple myeloma. It does not indicate endorsement by Celgene Corporation of an organization or its communications.

Your healthcare team is your best source of information.

Was this helpful?

Brought to you by Celgene Corporation. | Intended for a US audience.